Therapy of core binding factor acute myeloid leukemia

Incremental improvements toward better long-term results

Vijaya R Bhatt, Hagop Kantarjian, Jorge E. Cortes, Farhad Ravandi, Gautam Borthakur

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Core Binding Factors
Acute Myeloid Leukemia
Cytarabine
Therapeutics
PubMed
Language
Clinical Trials

Keywords

  • Chemotherapy
  • High-dose cytarabine
  • Inversion (16)
  • Response
  • Translocation (8;21)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Therapy of core binding factor acute myeloid leukemia : Incremental improvements toward better long-term results. / Bhatt, Vijaya R; Kantarjian, Hagop; Cortes, Jorge E.; Ravandi, Farhad; Borthakur, Gautam.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 2, 01.01.2013, p. 153-158.

Research output: Contribution to journalArticle

Bhatt, Vijaya R ; Kantarjian, Hagop ; Cortes, Jorge E. ; Ravandi, Farhad ; Borthakur, Gautam. / Therapy of core binding factor acute myeloid leukemia : Incremental improvements toward better long-term results. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 2. pp. 153-158.
@article{735a966e560b4335b72e2c80153a9543,
title = "Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results",
abstract = "Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40{\%} to 50{\%} at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.",
keywords = "Chemotherapy, High-dose cytarabine, Inversion (16), Response, Translocation (8;21)",
author = "Bhatt, {Vijaya R} and Hagop Kantarjian and Cortes, {Jorge E.} and Farhad Ravandi and Gautam Borthakur",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.clml.2012.11.006",
language = "English (US)",
volume = "13",
pages = "153--158",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Therapy of core binding factor acute myeloid leukemia

T2 - Incremental improvements toward better long-term results

AU - Bhatt, Vijaya R

AU - Kantarjian, Hagop

AU - Cortes, Jorge E.

AU - Ravandi, Farhad

AU - Borthakur, Gautam

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

AB - Background: Despite being considered as good prognostic acute myelogenous leukemia (AML), the long-term survival rate in core binding factor (CBF) AML leaves room for substantial improvement. Materials and Methods: We reviewed relevant English language literature related to treatment of CBF AML available in PubMed. Review also included meeting abstracts. Results: Multicycle high dose cytarabine in consolidation improves remission duration but larger groups report overall survival in the range of 40% to 50% at 5 years or longer. Conclusions: Concerted effort is needed toward improving outcomes in CBF AML through clinical trials and risk-adapted approach.

KW - Chemotherapy

KW - High-dose cytarabine

KW - Inversion (16)

KW - Response

KW - Translocation (8;21)

UR - http://www.scopus.com/inward/record.url?scp=84877314816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877314816&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.11.006

DO - 10.1016/j.clml.2012.11.006

M3 - Article

VL - 13

SP - 153

EP - 158

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -